Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus Journal Article


Authors: Petrowsky, H.; Roberts, G. D.; Kooby, D. A.; Burt, B. M.; Bennett, J. J.; Delman, K. A.; Stanziale, S. F.; Delohery, T. M.; Tong, W. P.; Federoff, H. J.; Fong, Y.
Article Title: Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus
Abstract: G207 is an oncolytic herpes simplex virus (HSV) which is attenuated by inactivation of viral ribonucleotide reductase (RR) and deletion of both γ134.5 genes. The cellular counterparts that can functionally substitute for viral RR and the carboxyl-terminal domain of ICP34.5 are cellular RR and the corresponding homologous domain of the growth arrest and DNA damage protein 34 (GADD34), respectively. Because the thymidylate synthetase (TS) inhibitor fluorodeoxyuridine (FUdR) can alter expression of cellular RR and GADD34, we examined the effect of FUdR on G207 bioactivity with the hypothesis that FUdR-induced cellular changes will alter viral proliferation and cytotoxicity. Replication of wild-type HSV-1 was impaired in the presence of 10 nM FUdR, whereas G207 demonstrated increased replication under the same conditions. Combined use of FUdR and G207 resulted in synergistic cytotoxicity. FUdR exposure caused elevation of RR activity at 10 and 100 nM, whereas GADD34 was induced only at 100 nM. The effect of enhanced viral replication by FUdR was suppressed by hydroxyurea, a known inhibitor of RR. These results demonstrate that the growth advantage of G207 in FUdR-treated cells is primarily based on an RR-dependent mechanism. Although our findings show that TS inhibition impairs viral replication, the FUdR-induced RR elevation may overcome this disadvantage, resulting in enhanced replication of G207. These data provide the cellular basis for the combined use of RR-negative HSV mutants and TS inhibitors in the treatment of cancer.
Keywords: controlled study; human cell; hydroxyurea; nonhuman; proteins; animals; cell cycle proteins; cell cycle; gene expression; cytotoxicity; tumor cells, cultured; cercopithecus aethiops; genes, reporter; herpesvirus 1, human; virus replication; floxuridine; herpes simplex virus; virus mutant; antigens, differentiation; vero cells; mutagenesis, insertional; viral proteins; virus activation; antiviral agents; virus attenuation; beta-galactosidase; ribonucleotide reductase; virogenesis; virus inhibition; virus cell interaction; humans; human; priority journal; article; ribonucleotide reductases
Journal Title: Journal of Virology
Volume: 75
Issue: 15
ISSN: 0022-538X
Publisher: American Society for Microbiology  
Date Published: 2001-08-01
Start Page: 7050
End Page: 7058
Language: English
DOI: 10.1128/jvi.75.15.7050-7058.2001
PUBMED: 11435585
PROVIDER: scopus
PMCID: PMC114433
DOI/URL:
Notes: Export Date: 21 May 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. William Ping-Yiu Tong
    158 Tong
  2. Keith Delman
    19 Delman
  3. Bryan M Burt
    18 Burt
  4. Joseph J Bennett
    19 Bennett
  5. David Kooby
    25 Kooby
  6. Yuman Fong
    775 Fong